SCHEMBL4194518

SCHEMBL4194518

O=C(OO)C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 9/20 0.65
NPSR1 Q6W5P4 1/20 0.44
CYP1A2 P05177 1/20 0.43
ALDH1A1 P00352 1/20 0.43
ALOX15 P16050 1/20 0.43
KCNE1 P15382 1/20 0.41
KCNQ1 P51787 1/20 0.41
KMT2A Q03164 2/20 0.40
MAPT P10636 2/20 0.40
CES1 P23141 1/20 0.39
CYP2C19 P33261 2/20 0.39
HIF1A Q16665 1/20 0.39
MEN1 O00255 1/20 0.39
CHRM3 P20309 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tert-Butyl Hydroperoxide SCHEMBL5908603 0.90 KCNN4 (0.60) KCNN4NPSR1CYP1A2ALDH1A1ALOX15
SCHEMBL7587514 0.83 KCNN4 (0.68) KCNN4NPSR1CYP1A2ALDH1A1ALOX15
SCHEMBL11229258 0.81 KCNN4 (0.48) KCNN4CYP1A2ALDH1A1ALOX15KMT2A
SCHEMBL11080904 0.79 KCNN4 (0.63) KCNN4NPSR1CYP1A2ALDH1A1ALOX15
SCHEMBL705717 0.79 KCNN4 (0.63) KCNN4NPSR1CYP1A2ALDH1A1ALOX15
SCHEMBL3885874 0.79 KCNN4 (0.63) KCNN4NPSR1CYP1A2ALDH1A1ALOX15
SCHEMBL7671036 0.79 KCNN4 (0.63) KCNN4NPSR1CYP1A2ALDH1A1ALOX15
SCHEMBL9513234 0.79 KCNN4 (0.47) KCNN4CYP1A2ALDH1A1ALOX15KMT2A
SCHEMBL11080901 0.79 KCNN4 (0.63) KCNN4NPSR1CYP1A2ALDH1A1ALOX15
SCHEMBL30956641 0.79 KCNN4 (0.63) KCNN4NPSR1CYP1A2ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250298331-A1 TONER CANON KABUSHIKI KAISHA (JP) 2025-09-25 US disclosed
US-12306581-B2 Toner CANON KABUSHIKI KAISHA (JP) 2025-05-20 US disclosed
US-20250093791-A1 TONER CANON KABUSHIKI KAISHA (JP) 2025-03-20 US disclosed
US-11642333-B2 Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromide ANOVENT PHARMACEUTICAL (U.S.), LLC (US) 2023-05-09 US disclosed
US-20220214630-A1 TONER CANON KABUSHIKI KAISHA (JP) 2022-07-07 US disclosed
CN-114514256-A Ultra high end controlled free radical polymerization 巴斯夫涂料有限公司 2022-05-17 CN disclosed
CN-114265290-A Textile custom printed with antimicrobial nanoparticles 施乐公司 2022-04-01 CN disclosed
CN-106249556-B Electrostatic image developing toner, electrostatic image developer, and toner cartridge 富士施乐株式会社 2020-04-10 CN disclosed
US-10139743-B2 Toners for developing electrostatic images and production method thereof SAMSUNG ELECTRONICS CO., LTD. (KR) 2018-11-27 US disclosed
US-9715185-B2 Electrostatic-image developing toner, electrostatic-image developer, and toner cartridge FUJI XEROX CO., LTD. (JP) 2017-07-25 US disclosed
US-20170205723-A1 TONERS FOR DEVELOPING ELECTROSTATIC IMAGES AND PRODUCTION METHOD THEREOF SAMSUNG ELECTRONICS CO., LTD. (KR) 2017-07-20 US disclosed
EP-3193213-A1 TONERS FOR DEVELOPING ELECTROSTATIC IMAGES AND PRODUCTION METHOD THEREOF Samsung Electronics Co., Ltd (KR) 2017-07-19 EP disclosed
US-20160357120-A1 ELECTROSTATIC-IMAGE DEVELOPING TONER, ELECTROSTATIC-IMAGE DEVELOPER, AND TONER CARTRIDGE FUJI XEROX CO., LTD. (JP) 2016-12-08 US disclosed
US-20090016788-A1 Image forming method FUJI XEROX CO., LTD. (JP) 2009-01-15 US disclosed
US-20050208412-A1 Image forming method FUJI XEROX CO., LTD. (JP) 2005-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11642333-B2 Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromide PDCD2L, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UBE3C KCNN4 689/4885NPSR1 2121/4885CYP1A2 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.